<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DIAZEPAM- diazepam solution </strong><br>Precision Dose Inc.<br></p></div>
<h1>DIAZEPAM Oral Solution<br> 5 mg per 5 mL<br> CIV</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">R<span class="Sub">x</span> only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Each 5 mL of Oral Solution contains:</p>
<p>Diazepam        5 mg</p>
<p><span class="Italics">Inactive Ingredients:</span></p>
<p>The wintergreen-spice flavored 5 mg/5 mL Oral Solution contains bitterness modifier, citric acid, D&amp;C Yellow No. 10, FD&amp;C Red No. 40, flavoring, polyethylene glycol, propylene glycol, sodium citrate, sorbitol, and water.</p>
<p>Diazepam is a benzodiazepine derivative. Chemically, diazepam is 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2<span class="Italics">H</span>-1,4-benzodiazepin-2-one. It is a colorless crystalline compound, insoluble in water and has a molecular weight of 284.74. Its structural formula is as follows:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=78d5a77d-5ca7-4f16-b4d0-fce86456593c&amp;name=diazepam-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">In animals diazepam appears to act on parts of the limbic system, the thalamus and hypothalamus, and induces calming effects. Diazepam, unlike chlorpromazine and reserpine, has no demonstrable peripheral autonomic blocking action, nor does it produce extrapyramidal side effects; however, animals treated with diazepam do have a transient <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> at higher doses. Diazepam was found to have transient cardiovascular depressor effects in dogs. Long-term experiments in rats revealed no disturbances of endocrine function.</p>
<p>Oral LD<span class="Sub">50</span> of diazepam is 720 mg/kg in mice and 1240 mg/kg in rats. Intraperitoneal administration of 400 mg/kg to a monkey resulted in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> on the sixth day.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>Reproduction Studies</h2>
<p class="First">A series of rat reproduction studies was performed with diazepam in oral doses of 1, 10, 80 and 100 mg/kg. At 100 mg/kg there was a decrease in the number of pregnancies and surviving offspring in these rats. Neonatal survival of rats at doses lower than 100 mg/kg was within normal limits. Several neonates in these rat reproduction studies showed skeletal or other defects. Further studies in rats at doses up to and including 80 mg/kg/day did not reveal teratological effects on the offspring.</p>
<p>In humans, measurable blood levels of diazepam were obtained in maternal and cord blood, indicating placental transfer of the drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Diazepam is indicated for the management of <span class="product-label-link" type="condition" conceptid="442077" conceptname="Anxiety disorder">anxiety disorders</span> or for the short-term relief of the symptoms of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>. <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> or <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> associated with the stress of everyday life usually does not require treatment with an anxiolytic.</p>
<p>In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, impending or <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">acute delirium</span> tremens and hallucinosis.</p>
<p>Diazepam is a useful adjunct for the relief of skeletal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span> due to reflex spasm to local pathology (such as <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the muscles or joints, or secondary to <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>); <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">spasticity</span> caused by upper motor neuron disorders (such as <span class="product-label-link" type="condition" conceptid="4134120" conceptname="Cerebral palsy">cerebral palsy</span> and <span class="product-label-link" type="condition" conceptid="192606" conceptname="Paraplegia">paraplegia</span>); <span class="product-label-link" type="condition" conceptid="4259277" conceptname="Athetosis">athetosis</span>; and stiff-man syndrome.</p>
<p>Oral diazepam may be used adjunctively in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>, although it has not proved useful as the sole therapy.</p>
<p>The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="CONTRAINDICATIONS"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Diazepam is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to this drug and, because of lack of sufficient clinical experience, in children under 6 months of age. It may be used in patients with <span class="product-label-link" type="condition" conceptid="435262" conceptname="Primary open angle glaucoma">open angle glaucoma</span> who are receiving appropriate therapy, but is contraindicated in acute narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WARNINGS"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Diazepam is not of value in the treatment of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> patients and should not be employed in lieu of appropriate treatment. As is true of most preparations containing CNS-acting drugs, patients receiving diazepam should be cautioned against engaging in hazardous occupations requiring complete mental alertness such as operating machinery or driving a motor vehicle.</p>
<p>As with other agents which have anticonvulsant activity, when diazepam is used as an adjunct in treating <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>, the possibility of an increase in the frequency and/or severity of <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">grand mal seizures</span> may require an increase in the dosage of standard anticonvulsant medication. Abrupt withdrawal of diazepam in such cases may also be associated with a temporary increase in the frequency and/or severity of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p>Since diazepam has a central nervous system depressant effect, patients should be advised against the simultaneous ingestion of alcohol and other CNS-depressant drugs during diazepam therapy.</p>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.1"></a><p></p>
<h2>Usage in Pregnancy</h2>
<p class="First"><span class="Bold">An increased risk of congenital malformations associated with the use of minor tranquilizers (diazepam, meprobamate and chlordiazepoxide) during the first trimester of pregnancy has been suggested in several studies. Because use of these drugs is rarely a matter of urgency, their use during this period should almost always be avoided. The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered. Patients should be advised that if they become pregnant during therapy, or intend to become pregnant, they should communicate with their physicians about the desirability of discontinuing the drug.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>Management of Overdosage</h2>
<p class="First">Manifestations of diazepam overdosage include <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4044603" conceptname="Hyporeflexia">diminished reflexes</span>. Respiration, pulse and blood pressure should be monitored, as in all cases of drug overdosage, although, in general, these effects have been minimal following overdosage. General supportive measures should be employed, along with immediate gastric lavage. Intravenous fluids should be administered and an adequate airway maintained. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> may be combated by the use of norepinephrine or metaraminol. Dialysis is of limited value. As with the management of intentional overdosage with any drug, it should be borne in mind that multiple agents may have been ingested.</p>
<p>Flumazenil, a specific benzodiazepine receptor antagonist, is indicated for the complete or partial reversal of the sedative effects of benzodiazepines and may be used in situations when an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with a benzodiazepine is known or suspected. Prior to the administration of flumazenil, necessary measures should be instituted to secure airway, ventilation, and intravenous access. Flumazenil is intended as an adjunct to, not as a substitute for, proper management of benzodiazepine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Patients treated with flumazenil should be monitored for re-sedation, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, and other residual benzodiazepine effects for an appropriate period after treatment.<span class="Bold"> The prescriber should be aware of a risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> in association with flumazenil treatment, particularly in long-term benzodiazepine users and in cyclic antidepressant <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. </span>The complete flumazenil package insert including<span class="Bold"> CONTRAINDICATIONS, WARNINGS, </span>and<span class="Bold"> PRECAUTIONS </span>should be consulted prior to use.</p>
<p>Withdrawal symptoms of the barbiturate type have occurred after the discontinuation of benzodiazepines (see<span class="Bold"><a href="#DAD"> DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span> </a></span>section).</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRECAUTIONS"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">If diazepam is to be combined with other psychotropic agents or anticonvulsant drugs, careful consideration should be given to the pharmacology of the agents to be employed–particularly with known compounds which may potentiate the action of diazepam such as phenothiazines, narcotics, barbiturates, MAO inhibitors and other antidepressants. The usual precautions are indicated for severely depressed patients or those in whom there is any evidence of latent <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; particularly the recognition that suicidal tendencies may be present and protective measures may be necessary. The usual precautions in treating patients with impaired renal or hepatic function should be observed.</p>
<p>In elderly and debilitated patients, it is recommended that the dosage be limited to the smallest effective amount to preclude the development of <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> or oversedation (2 mg to 2 1/2 mg once or twice daily, initially, to be increased gradually as needed and tolerated).</p>
<p>The clearance of diazepam and certain other benzodiazepines can be delayed in association with Tagamet (cimetidine) administration. The clinical significance of this is unclear.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.1"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">To assure the safe and effective use of benzodiazepines, patients should be informed that, since benzodiazepines may produce psychological and physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, it is advisable that they consult with their physician before either increasing the dose or abruptly discontinuing this drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Side effects most commonly reported were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>. Infrequently encountered were <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, changes in libido, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, changes in <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. Paradoxical reactions such as acute hyperexcited states, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, increased <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">muscle spasticity</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4327815" conceptname="Feeling angry">rage</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disturbances</span> and stimulation have been reported; should these occur, use of the drug should be discontinued.</p>
<p>Because of isolated reports of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, periodic blood counts and liver function tests are advisable during long-term therapy. Minor changes in EEG patterns, usually low-voltage fast activity, have been observed in patients during and after diazepam therapy and are of no known significance.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="DAD"></a><a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Diazepam Oral Solution is classified by the Drug Enforcement Administration as a Schedule IV controlled substance.</p>
<p>Withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (e.g., <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, abdominal and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>), have occurred following abrupt discontinuance of diazepam. The more severe withdrawal symptoms have usually been limited to those patients who received excessive doses over an extended period of time. Generally milder withdrawal symptoms (e.g., <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>) have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. Consequently, after extended therapy, abrupt discontinuance should generally be avoided and a gradual dosage tapering schedule followed. Addiction-prone individuals (such as drug addicts or alcoholics) should be under careful surveillance when receiving diazepam or other psychotropic agents because of the predisposition of such patients to <span class="product-label-link" type="condition" conceptid="4036424" conceptname="Drug tolerance">habituation</span> and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Dosage should be individualized for maximum beneficial effect. While the usual daily dosages given below will meet the needs of most patients, there will be some who may require higher doses. In such cases dosage should be increased cautiously to avoid adverse effects.</p>
<table class="Noautorules" width="100%">
<col align="left" valign="top" width="55%">
<col align="left" valign="top" width="45%">
<thead><tr>
<th align="left"><span class="Italics">Adults:</span></th>
<th align="left"><span class="Italics">Usual Daily Dosage</span></th>
</tr></thead>
<tbody>
<tr>
<td align="left"><span class="Italics">Management of <span class="product-label-link" type="condition" conceptid="442077" conceptname="Anxiety disorder">Anxiety Disorders</span> and Relief of Symptoms of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>.</span></td>
<td align="left">Depending upon severity of symptoms – 2 mg to 10 mg, 2 to 4 times daily.</td>
</tr>
<tr>
<td align="left"><span class="Italics">Symptomatic Relief in Acute Alcohol Withdrawal.</span></td>
<td align="left">10 mg, 3 or 4 times during the first 24 hours, reducing to 5 mg, 3 or 4 times daily as needed.</td>
</tr>
<tr>
<td align="left"><span class="Italics">Adjunctively for Relief of Skeletal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle Spasm</span>.</span></td>
<td align="left">2 mg to 10 mg, 3 or 4 times daily.</td>
</tr>
<tr>
<td align="left"><span class="Italics">Adjunctively in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsive Disorders</span>.</span></td>
<td align="left">2 mg to 10 mg, 2 to 4 times daily.</td>
</tr>
<tr>
<td align="left"><span class="Italics">Geriatric Patients or in the presence of debilitating disease.</span></td>
<td align="left">2 mg to 2 1/2 mg, 1 or 2 times daily initially; increase gradually as needed and tolerated.</td>
</tr>
<tr>
<td align="left"><span class="Bold Italics">Children:</span></td>
<td align="left"></td>
</tr>
<tr>
<td align="left"><span class="Italics">Because of varied responses to CNS-acting drugs, initiate therapy with lowest dose and increase as required. Not for use in children under 6 months.</span></td>
<td align="left">1 mg to 2 1/2 mg, 3 or 4 times daily initially; increase gradually as needed and tolerated.</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">Diazepam Oral Solution, 5 mg per 5 mL (Orange-colored, wintergreen-spice flavored solution)</span></p>
<p>NDC 68094-750-62<br>5 mL per unit dose cup<br>Thirty (30) cups per shipper</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<p class="First">Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]</p>
<p>Dispense in tight, light-resistant container as defined in the USP/NF.</p>
<p><span class="Bold">PROTECT FROM LIGHT.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First"><span class="Bold">Manufactured By:<br>Roxane Laboratories, Inc.<br>Columbus, OH 43216</span></p>
<p><span class="Bold">Packaged By:<br>Precision Dose, Inc.<br>S. Beloit, IL 61080</span></p>
<p>LI853 Rev. 10/11</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mL Cup Label</h1>
<p class="First">NDC 68094-750-59<br><span class="Bold">PrecisionDose™</span></p>
<p><span class="Bold">DIAZEPAM<br>Oral Solution<br>5 mg per 5 mL<br>CIV</span></p>
<p>Pkg: Precision Dose, Inc., S. Beloit, IL 61080</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 5 mL Cup Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=78d5a77d-5ca7-4f16-b4d0-fce86456593c&amp;name=diazepam-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DIAZEPAM 		
					</strong><br><span class="contentTableReg">diazepam solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68094-750(NDC:0054-3188)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Diazepam</strong> (Diazepam) </td>
<td class="formItem">Diazepam</td>
<td class="formItem">5 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">WINTERGREEN</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68094-750-62</td>
<td class="formItem">3  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68094-750-59</td>
<td class="formItem">5 mL in 1 CUP, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA070928</td>
<td class="formItem">02/22/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Precision Dose Inc.
							(035886746)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ed2bb1ac-4699-4edb-a344-c9cf1f71c49d</div>
<div>Set id: 78d5a77d-5ca7-4f16-b4d0-fce86456593c</div>
<div>Version: 1</div>
<div>Effective Time: 20120223</div>
</div>
</div> <div class="DistributorName">Precision Dose Inc.</div></p>
</body></html>
